RxDoctor Payments Data

Kathiria Plascencia

Family · Newport Beach, CANPI 1174261523

Payments from drug & device makers

$8,516in general payments, 2019–2025

Across 69 payments — averaging $123.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$4K
  • Sanofi$1K
  • Johnson & Johnson$1K
  • TG Therapeutics, Inc.$948
  • Novartis$427
  • EMD Serono, Inc.$174
  • plus $613 from 10 others

What the payments were for

  • Consulting fees$2,88334%
  • Speaking & faculty fees$1,99523%
  • Travel & lodging$1,29315%
  • Food & beverage$2,30527%
  • Education$390%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,516 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$32,934
Medicare patients
91
Services billed
1,379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Teriflunomide19$40,337
Emgality PenGalcanezumab-Gnlm24$30,752
UbrelvyUbrogepant17$25,237
Nurtec OdtRimegepant Sulfate11$17,238
Dalfampridine ErDalfampridine12$11,500
Aimovig AutoinjectorErenumab-Aooe13$10,638
Topiramate ErTopiramate17$3,793
Baclofen56$1,620
Modafinil15$1,156
Memantine Hcl32$1,147
Gabapentin93$1,007
Zonisamide17$915
Amitriptyline Hcl30$685
RizatriptanRizatriptan Benzoate22$476
Naratriptan Hcl11$242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$35$25,23717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →